Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries

Louise Linde; Lykke M Ørnbjerg; Stylianos Georgiadis; Simon H Rasmussen; Ulf Lindström; Johan Askling; Brigitte Michelsen; Daniela Di Giuseppe; Johan K Wallman; Björn Guðbjörnsson; Þorvarður Jón Löve; Dan C Nordström; Timo Yli-Kerttula; Lucie Nekvindová; Jiří Vencovský; Florenzo Iannone; Alberto Cauli; Anne Gitte Loft; Bente Glintborg; Karin Laas; Ziga Rotar; Matija Tomšič; Gary J Macfarlane; Burkhard Möller; Marleen van de Sande; Catalin Codreanu; Michael J Nissen; Merih Birlik; Sukran Erten; Maria J Santos; Elsa Vieira-Sousa; Merete L Hetland; Mikkel Østergaard

doi:10.1093/rheumatology/kead284

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries

Louise Linde, Lykke M Ørnbjerg, Stylianos Georgiadis, Simon H Rasmussen, Ulf Lindström, Johan Askling, Brigitte Michelsen, Daniela Di Giuseppe, Johan K Wallman, Björn Guðbjörnsson, Þorvarður Jón Löve, Dan C Nordström, Timo Yli-Kerttula, Lucie Nekvindová, Jiří Vencovský, Florenzo Iannone, Alberto Cauli, Anne Gitte Loft, Bente Glintborg, Karin LaasZiga Rotar, Matija Tomšič, Gary J Macfarlane, Burkhard Möller, Marleen van de Sande, Catalin Codreanu, Michael J Nissen, Merih Birlik, Sukran Erten, Maria J Santos, Elsa Vieira-Sousa, Merete L Hetland, Mikkel Østergaard

Research output: Contribution to journal › Article › peer-review

1 Downloads (Pure)

Abstract

OBJECTIVES: In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries.

METHODS: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes, were defined as common predictors.

RESULTS: In the pooled cohort (n = 13 369), six-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6,954, n = 5,275 and n = 13 369, respectively). Baseline predictors of remission, moderate response and 12-month drug retention were identified, five common across all three outcomes. Odds ratios (95% confidence interval) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (< 2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP >10 vs ≤ 10 mg/l: 1.52 (1.22-1.89) and one mm increase in patient fatigue score: 0.99 (0.98-0.99).

CONCLUSION: Baseline predictors of remission, response and adherence to TNFi were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalisable from the country- to disease-level.

Original language	English
Journal	Rheumatology (Oxford, England)
DOIs	https://doi.org/10.1093/rheumatology/kead284
Publication status	E-pub ahead of print - 14 Jun 2023

Bibliographical note

Access to Document

10.1093/rheumatology/kead284

kead284Accepted author manuscript, 591 KBLicence: CC BY-NC

Cite this

Linde, L., Ørnbjerg, L. M., Georgiadis, S., Rasmussen, S. H., Lindström, U., Askling, J., Michelsen, B., Di Giuseppe, D., Wallman, J. K., Guðbjörnsson, B., Löve, Þ. J., Nordström, D. C., Yli-Kerttula, T., Nekvindová, L., Vencovský, J., Iannone, F., Cauli, A., Loft, A. G., Glintborg, B., ... Østergaard, M. (2023). Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries. Rheumatology (Oxford, England). Advance online publication. https://doi.org/10.1093/rheumatology/kead284

@article{be5579941223424d8a676f5ceb34c8fa,

title = "Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries",

abstract = "OBJECTIVES: In bio-na{\"i}ve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries.METHODS: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes, were defined as common predictors.RESULTS: In the pooled cohort (n = 13 369), six-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6,954, n = 5,275 and n = 13 369, respectively). Baseline predictors of remission, moderate response and 12-month drug retention were identified, five common across all three outcomes. Odds ratios (95% confidence interval) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (< 2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP >10 vs ≤ 10 mg/l: 1.52 (1.22-1.89) and one mm increase in patient fatigue score: 0.99 (0.98-0.99).CONCLUSION: Baseline predictors of remission, response and adherence to TNFi were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalisable from the country- to disease-level.",

author = "Louise Linde and {\O}rnbjerg, {Lykke M} and Stylianos Georgiadis and Rasmussen, {Simon H} and Ulf Lindstr{\"o}m and Johan Askling and Brigitte Michelsen and {Di Giuseppe}, Daniela and Wallman, {Johan K} and Bj{\"o}rn Gu{\dh}bj{\"o}rnsson and L{\"o}ve, {{\TH}orvar{\dh}ur J{\'o}n} and Nordstr{\"o}m, {Dan C} and Timo Yli-Kerttula and Lucie Nekvindov{\'a} and Ji{\v r}{\'i} Vencovsk{\'y} and Florenzo Iannone and Alberto Cauli and Loft, {Anne Gitte} and Bente Glintborg and Karin Laas and Ziga Rotar and Matija Tom{\v s}i{\v c} and Macfarlane, {Gary J} and Burkhard M{\"o}ller and {van de Sande}, Marleen and Catalin Codreanu and Nissen, {Michael J} and Merih Birlik and Sukran Erten and Santos, {Maria J} and Elsa Vieira-Sousa and Hetland, {Merete L} and Mikkel {\O}stergaard",

note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.",

year = "2023",

month = jun,

day = "14",

doi = "10.1093/rheumatology/kead284",

language = "English",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

}

Linde, L, Ørnbjerg, LM, Georgiadis, S, Rasmussen, SH, Lindström, U, Askling, J, Michelsen, B, Di Giuseppe, D, Wallman, JK, Guðbjörnsson, B , Löve, ÞJ, Nordström, DC, Yli-Kerttula, T, Nekvindová, L, Vencovský, J, Iannone, F, Cauli, A, Loft, AG, Glintborg, B, Laas, K, Rotar, Z, Tomšič, M, Macfarlane, GJ, Möller, B, van de Sande, M, Codreanu, C, Nissen, MJ, Birlik, M, Erten, S, Santos, MJ, Vieira-Sousa, E, Hetland, ML & Østergaard, M 2023, 'Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries', Rheumatology (Oxford, England). https://doi.org/10.1093/rheumatology/kead284

TY - JOUR

T1 - Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor

T2 - results from 13 European registries

AU - Linde, Louise

AU - Ørnbjerg, Lykke M

AU - Georgiadis, Stylianos

AU - Rasmussen, Simon H

AU - Lindström, Ulf

AU - Askling, Johan

AU - Michelsen, Brigitte

AU - Di Giuseppe, Daniela

AU - Wallman, Johan K

AU - Guðbjörnsson, Björn

AU - Löve, Þorvarður Jón

AU - Nordström, Dan C

AU - Yli-Kerttula, Timo

AU - Nekvindová, Lucie

AU - Vencovský, Jiří

AU - Iannone, Florenzo

AU - Cauli, Alberto

AU - Loft, Anne Gitte

AU - Glintborg, Bente

AU - Laas, Karin

AU - Rotar, Ziga

AU - Tomšič, Matija

AU - Macfarlane, Gary J

AU - Möller, Burkhard

AU - van de Sande, Marleen

AU - Codreanu, Catalin

AU - Nissen, Michael J

AU - Birlik, Merih

AU - Erten, Sukran

AU - Santos, Maria J

AU - Vieira-Sousa, Elsa

AU - Hetland, Merete L

AU - Østergaard, Mikkel

PY - 2023/6/14

Y1 - 2023/6/14

N2 - OBJECTIVES: In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries.METHODS: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes, were defined as common predictors.RESULTS: In the pooled cohort (n = 13 369), six-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6,954, n = 5,275 and n = 13 369, respectively). Baseline predictors of remission, moderate response and 12-month drug retention were identified, five common across all three outcomes. Odds ratios (95% confidence interval) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (< 2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP >10 vs ≤ 10 mg/l: 1.52 (1.22-1.89) and one mm increase in patient fatigue score: 0.99 (0.98-0.99).CONCLUSION: Baseline predictors of remission, response and adherence to TNFi were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalisable from the country- to disease-level.

AB - OBJECTIVES: In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries.METHODS: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes, were defined as common predictors.RESULTS: In the pooled cohort (n = 13 369), six-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6,954, n = 5,275 and n = 13 369, respectively). Baseline predictors of remission, moderate response and 12-month drug retention were identified, five common across all three outcomes. Odds ratios (95% confidence interval) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (< 2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP >10 vs ≤ 10 mg/l: 1.52 (1.22-1.89) and one mm increase in patient fatigue score: 0.99 (0.98-0.99).CONCLUSION: Baseline predictors of remission, response and adherence to TNFi were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalisable from the country- to disease-level.

U2 - 10.1093/rheumatology/kead284

DO - 10.1093/rheumatology/kead284

M3 - Article

C2 - 37314967

SN - 1462-0324

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

ER -

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this